 |
|
|
| |
100% SVR12 With Ledipasvir/Sofosbuvir ± Ribavirin for 12 Weeks in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Who Previously Failed Protease Inhibitor + Pegylated Interferon-a + Ribavirin Therapy
|
| |
| |
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
Masao Omata,1 Tetsuo Takehara,2 Osamu Yokosuka,3 Naoya Sakamoto,4 Masaaki Korenaga,5 Hitoshi Mochizuki,1 Kunio Nakane,6 Hirayuki Enomoto,7 Mikio Yanase,5 Hidenori Toyoda,8 Fusao Ikeda,9 Takuya Genda,10 Takeji Umemura,11 Hiroshi Yatsuhashi,12 Tatsuya Ide,13 Nobuo Toda,14 Kazushige Nirei,15
Yoshiyuki Ueno,16 Yoichi Nishigaki,17 Shampa De-Oertel,18 Bing Gao,18 Hadas Dvory-Sobol,18 Akinobu Ishizaki,19 Masa Omote,19 Phillip S. Pang,18 Steven J. Knox,18 William T. Symonds,18 John G. McHutchison,18 Namiki Izumi,20 Masashi Mizokami,5 on behalf of the GS-US-337-0113 Study Team
1Yamanashi Prefectural Hospital Organization, Yamanashi, Japan; 2Osaka University Hospital, Osaka, Japan; 3Chiba University, Chiba, Japan; 4Hokkaido University, Hokkaido, Japan; 5National Center for Global Health and Medicine, Tokyo, Japan; 6Akita City Hospital, Akita, Japan; 7Hyogo College of Medicine, Hyogo, Japan; 8Ogaki Municipal Hospital, Gifu, Japan; 9Okayama University, Okayama, Japan; 10Juntendo University, Tokyo, Japan;
11Shinshu University, Nagano, Japan; 12National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan; 13Kurume University, Fukuoka, Japan; 14Mitsui Memorial Hospital, Tokyo, Japan; 15Nihon University, Tokyo, Japan; 16Yamagata University, Yamagata, Japan; 17Gifu Municipal Hospital, Gifu, Japan; 18Gilead Sciences, Inc., Foster City, California, USA; 19Gilead Sciences KK, Tokyo, Japan; 20Musashino Red Cross Hospital, Tokyo, Japan
|
| |
|
|
|
|
|
